See the DrugPatentWatch profile for tisagenlecleucel
What is tisagenlecleucel (Kymriah)?
Tisagenlecleucel is an autologous CAR T-cell therapy used for certain blood cancers, where a patient’s own T cells are genetically modified to target cancer cells. [1]
What conditions is it approved for?
Tisagenlecleucel is approved for specific indications in hematologic malignancies (not all leukemia or lymphoma types). Exact approved use depends on the country and the patient population defined by the regulator label. [1]
How is it given (what the treatment pathway looks like)?
Treatment typically involves steps that match CAR T workflows: collecting the patient’s T cells, manufacturing the modified product, then giving a lymphodepleting chemotherapy before CAR T infusion. The precise regimen and timing vary by protocol and indication. [1]
What are the main risks patients ask about?
Key risks commonly associated with CAR T-cell therapies include cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Management usually involves monitoring and supportive care, sometimes with targeted treatments when symptoms occur. [1]
What does the number “29669225” mean here?
“29669225” by itself doesn’t identify the product, approval, or study without context. It could be an internal reference (for example, a record number in a database) or a citation ID in a system you’re using. If you tell me where you got it (website/app/database) or what it’s labeled as, I can map it more precisely.
Where can I find the authoritative label/details?
The most reliable source is the official product information for your country (e.g., the prescribing information or regulatory assessment documents) because dosing, patient eligibility, and safety guidance are label-specific. [1]
Sources
[1] https://www.kymriahpro.com/